Colleen Kusy
Stock Analyst at Baird
(0)
# 4202
Out of 5,240 analysts
51
Total ratings
25.00%
Success rate
-7.80%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Coherus BioSciences | Maintains: Outperform | 4 6 | 1.45 | 313.79% | 5 | Dec 5, 2024 | |
Enliven Therapeutics | Maintains: Outperform | 32 40 | 20.42 | 95.89% | 2 | Nov 15, 2024 | |
Spyre Therapeutics | Maintains: Outperform | 50 65 | 20.77 | 212.95% | 2 | Nov 13, 2024 | |
Apellis Pharmaceutic... | Maintains: Outperform | 92 55 | 27.69 | 98.63% | 10 | Nov 7, 2024 | |
Mersana Therapeutics | Maintains: Neutral | 4 3 | 0.64 | 368.75% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 18 17 | 7.88 | 115.74% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 35 37 | 22.39 | 65.25% | 3 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 27 25 | 9.9 | 152.53% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 105 | 72.37 | 45.09% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 160 | 3.15 | 4979.37% | 1 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 40 | n/a | n/a | 3 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 17 15 | n/a | n/a | 1 | Oct 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 17 14 | 0.64 | 2087.5% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 30 34 | 5.89 | 477.25% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 230 | 3.57 | 6342.58% | 1 | Nov 2, 2021 |